Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiaging methods and medicines for the memory.

William A Banks1, Susan A Farr

  • 1Department of Internal Medicine, Saint Louis University School of Medicine, MO 63104, USA. bankswa@slu.edu

Clinics in Geriatric Medicine
|June 9, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Insulin and Incretin Receptor Agonists Reciprocally Alter Their Blood-Brain Barrier Permeabilities.

International journal of molecular sciences·2026
Same author

Pontine pathology mediates common symptoms of blast-induced chronic mild traumatic brain injury.

Brain communications·2026
Same author

Lecanemab alters basement membrane collagen IV in viable microvessels isolated from brains with high Alzheimer's disease neuropathology.

Journal of Alzheimer's disease : JAD·2026
Same author

Role of the endothelial cell apolipoprotein E receptor 2 in modulating the effects of apoE3 and apoE4 on insulin blood-brain barrier transport.

PloS one·2026
Same author

Strategies for blood-brain barrier rejuvenation and repair.

Nature reviews. Drug discovery·2026
Same author

Enzyme replacement therapy for CLN1 batten disease that crosses the blood-brain-barrier.

Molecular genetics and metabolism·2026

Researchers are exploring how specific proteins, like amyloid-beta precursor protein (APP), contribute to Alzheimer's disease. Animal models suggest that targeting APP overproduction could reverse cognitive decline, offering new therapeutic avenues beyond unproven anti-aging remedies.

Area of Science:

  • Neuroscience
  • Pathology
  • Pharmacology

Background:

  • Alzheimer's disease (AD) research has identified pathological proteins as key contributors to its progression.
  • Amyloid-beta precursor protein (APP) has emerged as a significant focus due to its link with cognitive impairments.

Purpose of the Study:

  • To investigate the role of APP overproduction in cognitive deficits associated with Alzheimer's disease.
  • To explore the potential of animal models in developing therapeutics for reversing established AD.
  • To identify novel peptide and protein candidates for cognitive enhancement.

Main Methods:

  • Utilizing animal models to study the effects of APP overproduction on cognitive function.
  • Developing and testing therapeutics aimed at reversing the detrimental impacts of APP.

Related Experiment Videos

  • Analyzing other peptides and proteins for their influence on cognitive performance.

    • Main Results:

    • Animal models demonstrate that APP overproduction causes cognitive impairments.
    • Evidence suggests that established Alzheimer's disease may be reversible through targeted interventions.
    • Other peptides and proteins have been identified as potential modulators of cognitive function.

    Conclusions:

    • Targeting APP overproduction in animal models shows promise for reversing Alzheimer's disease.
    • Further research into various peptides and proteins may yield new therapeutic strategies for memory enhancement.
    • Scientifically-based approaches are crucial for developing effective treatments, distinguishing them from unproven anti-aging remedies.